Advanced search
Publication Cover
Leukemia & Lymphoma Volume 44, 2003 - Issue 2
Submit an article Journal homepage
30
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Advances in the Treatment of Multiple Myeloma: The Role of Thalidomide

Christian Ribas Discipline of Hematology and Hemotherapy, Medicine Department, Universidade Federal de São Paulo, UNIFESP/EPM, São Paulo, Brazil
&
Gisele W.B. Colleoni Discipline of Hematology and Hemotherapy, Medicine Department, Universidade Federal de São Paulo, UNIFESP/EPM, São Paulo, Brazil
Pages 291-298 | Published online: 01 Jul 2009

  • Podar, K., Tai, Y.T., Davies, F.E., Lentzsch, s., Sattle, M., Hideshima, T., Lin, B. K., Gupta, D., Shima, Y., Chauhan, D., Mitsiades, C., Raje, N., Richardson, P. and Anderson, K. C. (2001) "Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration", Blood 98, 428-435.
  • Greenlee, R. T., Murray, T., Bolden, S. and Wingo, P. A. (2000) "Cancer statistics", Cancer Journal for Clinicians 50, 7-33.
  • Bakkus, M. H., Van Riet, I., Van Camp, B. and Thielemans, K. (1994) "Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B-cell", British Journal of Haematology 87, 68-74.
  • Hallek, M., Bergsagel, P. L. and Anderson, K. C. (1998) "Multiple myeloma: increasing evidence for a multistep trasformation process", Blood 91, 3-21.
  • Kyle, R. A. (2001) "Diagnostic challenges and standard therapy", Seminars in Hematology 38(Suppl. 3), 11-14.
  • Gregory, W. M., Richards, M. A. and Malpas, J. S. (1992) "Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials", Journal of Clinical Oncology 10, 334-342.
  • No authors listed (1998) "Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group", Journal of Clinical Oncology 16, 3832-3842.
  • Crowley, J., Jacobson, J. and Alexanian, R. (2001) "Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience", Seminars in Hematology 38, 203-208.
  • Bladé, J. and Esteve, J. (2000) "Treatment approaches for relapsing and refractory multiple myeloma", Acta Oncologica 39, 843-847.
  • Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., lfrah, N., Payen, C. and Bataille, R. (1996) "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe français du Myeloma", New England Journal of Medicine 335, 91-97.
  • Attal, M. and Harousseau, J.L. (2001) "Randomized trial experience of the Intergroupe Francophone du Myeloma", Seminars in Hematology 38, 226-230.
  • Björkstrand, B. (2001) "European Group for Blood and Marrow Transplantation Registry Studies in Multiple Myeloma", Seminars in Hematology 38, 219-225.
  • Badros, A., Barlogie, B., Siegel, E., Cottier-Fox, M., Zangari, M., Fassas, A., Morris, C., Anaissie, E., Van Rhee, F. and Tricot, G. (2002) "Improved outcome of allogeneic transplantation in highrisk multiple myeloma patients after nomyeloablative conditioning", Journal of Clinical Oncology 20, 1295- 1303.
  • Guhrton, G., Tura, S., Ljungman, P., Blade, J., Brandt, L., Cavo, M., Facon, T., Gratwohl, A., Hagenbeek, A. and Jacobs, P. (1995) "Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma", Journal of Clinical Oncology 13, 1312-1322.
  • Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. and Dammacco, F. (1994) "Bone marrow angiogenesis and progression in multiple myeloma", British Journal of Haematology 87, 503-508.
  • Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. and Dammacco, F. (1999) "Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma", Blood 93, 3064-3073.
  • Munshi, N.C. and Wilson, C. (2001) "Increased microvessel density in newly diagnosed multiple myeloma carries a poor prognosis", Seminars in Oncology 28, 565-569.
  • Bellamy, W.T. (2001) "Expression of vascular endothelial growth factor and its receptor in multiple myeloma and other hematopoitetic malignancies", Seminars in Oncology 28, 577-582.
  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. and Barlogie, B. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", New England Journal of Medicine 341, 1565-1571.
  • Fujii, R., Yaccoby, S. and Epstein, J. (2000) "Control of myeloma with the antiangiogenic agent endostatin", Blood 96, 1555a (Abstract).
  • Rajkumar, S.V. and Witzig, T.E. (2000) "A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma", Cancer Treatment Reviews 26, 351-362.
  • Rujkumar, S.V. and Kyle, R.A. (2001) "Thalidomide in the treatment of plasma cell malignancies", Journal of Clinical Oncology 19, 3593-3595.
  • Barlogie, B., Zangari, M, Spencer, T., Fassas, A., Anaissie, E., Badros, A., Cromer, J. and Tricot, G. (2001) "Thalidomide in the management of multiple myeloma", Seminars in Hematology 38, 250-259.
  • Barlogie, B., Spencer, T., Tricot, G., Zeldis, J., Munshi, N., Zangari, M., Badros, A., Toor. A., Shaughnessy, J., Morris, C. and Desikan, R. (2000) "Long term follow-up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma", Blood 96, 5l4a (Abstract).
  • Zangari, M., Anáissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., Morris, C., Toor, A., Siegel, E., Fink, L. and Tricot, G. (2001) "Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotheapy", Blood 98, 1614-1615.
  • Cany, L., Fitoussi, O., Boiron, J.M. and Marit, G. (2002) "Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma", Journal of Clinical Oncology 20, 2212.
  • Barlogie, B., Tricot, G. and Anaissie, E. (2001) "Thalidomide in the management of multiple myeloma", Seminars in Oncology 28. 577-582.
  • Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. and Anderson, K.C (2000) "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy", Blood 96, 2943-2950.
  • Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. and Anderson, K.C. (2001) "Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma", Blood 98, 210-216.
  • Anderson, K.C. (2001) "Targeted therapy for multiple myeloma", Seminars in Hematotogy 38, 286-294.
  • Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M. and Mulm, C. (2000) "Frequent good partial remissions from thalidomide including best response even in patients with advanced refractory and relapsed myeloma", British Journal of Haematology 109, 89-96.
  • Yakoub-Agha, I., Attal, M., Dumontet, C., Moreau, P., Berthou, C., Lamy, T., Grosbois, B., Dauriac, C., Dorvaux, I., Bay, J.O., Monconduit, M., Harousseau, J.L., Duguet, C. and Facon, T. (2000) "Thalidomide in patients with advanced myeloma: survival prognostic factors", Blood 96, 167a (Abstract).
  • Raza, S.N., Veksler, Y., Sabir, T., Li, Z., Anderson, L. and Jagannath, S. (2000) "Durable response to thalidomide in relapsed/refractory multiple myeloma", Blood 96, 168a (Abstract).
  • Tosi, P., Ronconi, S., Zamagni, E., Cellini, C., Tura, S. and Cavo, M. (2000) "Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma", Blood 96, 296b (Abstract).
  • Prince, H.M., Biagi, J.J., Mitchell, P., Mileshkin, L., Seymour, J.F., Januszewicz, E.H., Wolf, M.M. and Westerman, D.A. (2000) "lnterferon-a-2b (IF) can be combined with thalidomide (Thal) in patients with multiple myeloma (MM)", Blood 96, 293b (Abstract).
  • Rodriguez, J., Oyama, Y. Burt, R.K. and Traynor, A.E. (2000) "Achievement of maximal disease response to thalidomide is limited by patient tolerance more often than disease resistance", Blood 96 294b (Abstract).
  • Grosbois, B., Bellissant, E., Moreau, P., Attal, M. and Zerbib, R. (2001) "Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM), A prospective study of 120 patients", Blood 98, 163a (Abstract).
  • Wechalekar, A.D., Sutton, D., Voralia, M., Stewart, A.K. and Chen. C.I. (2001) "Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma", Blood 98, 162a (Abstract).
  • Durie, B.G.M. and Stepan, D.E. (2001) "Low dose thalidomide alone and in combination: long term follow-up", Blond 98, 163a (Abstract).
  • Rujkumar, S.V., Dispcnzicri, A., Lacy, M., Geyer, S., Iturria, N., Fonseca, R., Hayman, S.R., Lust, J.A., Kyle, R., Greipp, P.R., Gertz, M.A. and Witzig, T.E. (2001) "Response rate and durability of response with thalidomide therapy for relapsed multiple myeloma (MM)", Blood 98, 162a (Abstract).
  • Rajkumar, S.V., Hayman, S.R., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Geyer, S., Wellik, L., Lust, J.A., Kyle, R.A., Greipp, P.R., Gertz, M.A. and Witzig, T.E. (2000) "Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thai) as first line therapy for newly diagnosed myeloma (MM)", Blood 96, 168a (Abstract).
  • Rajkumar, S.V., Hayman, S.R., Gertz, M.A., Dispenzieri, A., Lacy. M., Greipp, P.R., Geyer, S., Itturia, N., Fonseca, R., Lust, J.A., Kyle, R. and Witzig, T.E. (2001) "Combination therapy with thalidomide plus dexamethasone (Thal/Dex) for newly diagnosed myeloma (MM)", Blood 98, 849a (Abstract).
  • Kyle, R.A. and Rajkumar, S.V. (2001) "Therapeutic application of thalidomide in multiple myeloma", Seminars in Oncology 28, 583-587.
  • Dimopoulos, M.A., Zervas, K., Galani, E., Grigoraki, V. Vervessou, E., Samantas, E., Kiamouris, C., Gika, D., Papadimitriou, C. and Anagnostopoulos, N. (2000) "Thaliadomide and dexamethasone combination for multiple myeloma refractory to dexamethasone-based regimens", Blood 96, 286b (Abstract).
  • Weber, D.M., Rankin, K., Gavino, M., Delasalle, K. and Alexanian, R. (2000) "Thalidomide with dexamethasone for resistant multiple myeloma", Blood 96, 167a (Abstract).
  • Palumbo, A., Giaccone, L., Bringhen, S., Cavallo, F., Falco, P., Rus, C., Bertola, A., Pileri, A. and Boccadoro, M. (2001) "Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients", Blood 98, 162a (Abstract).
  • Tosi, P., Zamagni, E., Cellini, C., Cangini, D., Tura, S., Baccarani, M and Cavo, M (2001) "Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractory multiple myeloma", Blood 98, 163a (Abstract).
  • Kropff, M.H., Innig, G., Mitterer, M., Straka, C., Ostermann, H., Koch, O.M., Berdel, W.F., and Kienast, J. (2000) "Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma", Blood 96, 168a (Abstract).
  • Moehler, T.M., Neben, K., Hawighorst, H., Egerer, G., van Kaick, G., Ho, A.D. and Goldschmidt, H. (2000) "Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma", Blood 96, 290b (Abstract).
  • Srkalovic, G., Karam, M.A., Trebisky, B.M. and Hussein, M.A. (2000) "Treatment of refractory/relapsed multiple myeloma (MM) with combination of melphalan, thalidomide and decadron (MTD)". Blood 96, 294b (Abstract).
  • Dimopoulos, M., Panayiotidis, P., Grigoraki, V. Poziopoulos, C., Xilouri, I., Kiamouris, C., Tassidou, A., Gika, D., Stefanoudaki, K., Anagnostopoulos, N. and Anagnostou, D. (2001) "Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma", Blood 98, 164a (Abstract).
  • Barlogie, B. (2001) "High-dose therapy and innovative approaches to treatment of multiple myeloma", Seminars in Hematology 38(Suppl. 3), 21-27.
  • Alexanian, R., Weber, D.M., Giralt, S. and Delasalle, K.B. (2001) "Consolidation therapy of multiple myeloma with thalidomide-dexamethusone after intensive chemotherapy", Blood 98, 163a (Abstract).
  • Somlo, G., Yamamoto, N., Sarah, C., O'Donnell, M., Snyder, D., Sahebi, F., Kogut, N., Spielberger, R., Molina, A., Parker, P., Popplewell, L., Fung, R., Rodriguez, R., Stein, A., Krishnan, A., Chow, W., Lopez, F. and Forman, S. (2001) "Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon-a-2 (IF) with or without thalidomide (Thai) for multiple myeloma, High complete response rate and moderate toxicities", Blood 98, 685a (Abstract).
  • Thertulien, R., Barlogie, B., Fassas, A., Eddlemon, P., Zangari, M., Muwalla, F., Morris, C., Anaissie, E., Fox, M. and Tricot, G. (2001) "Hybrid MEL/DT PACE autotransplant regimen for multiple myeloma (MM)-safety and efficacy data in pilot study of 15 patients", Blood 98, 686a (Abstract).
  • Stirling, D. (2001) "Thalidomide: a novel template for anticancer drugs", Seminaras in Oncology 28, 602-606.
  • Tosi, P. and Cavo, M. (2002) "Thalidomide in multiple myeloma: state of art", Haematologica 87, 233-234.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.